![]() |
|
|
Vol. 296, Issue 3, 1023-1034, March 2001
College of Pharmacy, University of Kentucky, Lexington, Kentucky
(D.K.M., P.A.C., L.T., L.P.D.); and Behavioral Neuroscience Branch,
National Institute on Drug Abuse Addiction Research Center, Baltimore,
Maryland (J.M.W., P.M., S.R.G., J.B.A.)
Lobeline interacts with the dopamine transporter and vesicular
monoamine transporter, presynaptic proteins involved in dopamine storage and release. This study used rodent models to assess
lobeline-induced inhibition of the neurochemical and behavioral effects
of amphetamine. Rat striatal slices were preloaded with
[3H]dopamine and superfused with lobeline for 30 min, and
then with d-amphetamine (0.03-3.00 µM) plus lobeline
for 60 min. As predicted, lobeline (1-3 µM) intrinsically increased
3H overflow but did not inhibit
d-amphetamine-evoked 3H overflow.
Consequently, the effect of lobeline on
d-amphetamine-evoked endogenous dopamine and
dihydroxyphenylacetic acid overflow was assessed. Lobeline (0.1-1
µM) inhibited d-amphetamine (1 µM)-evoked dopamine
overflow but did not inhibit electrically evoked 3H
overflow, indicating a selective inhibition of this effect of d-amphetamine. To determine whether the in vitro results
translated into in vivo inhibition, the effect of lobeline (0.3-10.0
mg/kg) pretreatment on d-amphetamine (0.1-1.0
mg/kg)-induced hyperactivity in rats and on
d-methamphetamine (0.1-3.0 mg/kg)-induced hyperactivity in mice was determined. Doses of lobeline that produced no effect alone
attenuated the stimulant-induced hyperactivity. Lobeline also
attenuated the discriminative stimulus properties of
d-methamphetamine in rats. Acute, intermittent, or
continuous in vivo administration of lobeline (1-30 mg/kg) did not
deplete striatal dopamine content. Thus, lobeline inhibits
amphetamine-induced neurochemical and behavioral effects, and is not
toxic to dopamine neurons. These results support the hypothesis that
lobeline redistributes dopamine pools within the presynaptic terminal,
reducing pools available for amphetamine-induced release. Collectively,
the results support a role for lobeline as a potential pharmacotherapy
for psychostimulant abuse.
This article has been cited by other articles:
![]() |
D. J. Eyerman and B. K. Yamamoto Lobeline Attenuates Methamphetamine-Induced Changes in Vesicular Monoamine Transporter 2 Immunoreactivity and Monoamine Depletions in the Striatum J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 160 - 169. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Wilhelm, R. A. Johnson, P. G. Lysko, A. J. Eshleman, and A. Janowsky Effects of Methamphetamine and Lobeline on Vesicular Monoamine and Dopamine Transporter-Mediated Dopamine Release in a Cotransfected Model System J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 1142 - 1151. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. K. Miller, P. A. Crooks, G. Zheng, V. P. Grinevich, S. D. Norrholm, and L. P. Dwoskin Lobeline Analogs with Enhanced Affinity and Selectivity for Plasmalemma and Vesicular Monoamine Transporters J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 1035 - 1045. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. B. Harrod, L. P. Dwoskin, P. A. Crooks, J. E. Klebaur, and M. T. Bardo Lobeline Attenuates d-Methamphetamine Self-Administration in Rats J. Pharmacol. Exp. Ther., July 1, 2001; 298(1): 172 - 179. [Abstract] [Full Text] |
||||